Abstract

Aim of study – to estimate leptin gene (Arg223Gln) genotypes polymorphism in patients with coronary heart disease and obesity. Materials and Methods. 222 patients with the coronary heart disease (CHD) and obesity have been comprehensively examined. All patients were on treatment in cardiologic unit of KUZ of the Kharkiv city hospital № 27, which is the basic clinic of Department of Internal Medicine № 2 and Clinical Immunology and Allergology of the Kharkiv National Medical University of MH of Ukraine. The comparison group consisted of 115 ischemic heart disease patients with normal body weight. 35 practically healthy persons formed the control group. Groups were comparable in age and sex. The study didn't include the patients with the serious accompanying pathology of respiratory organs, digestion, kidneys and persons with oncological diseases. Results. In the control group there was the following distribution of leptin gene (Arg223Gln) alleles and genotypes polymorphism frequency: 15 people were allele A that made 42.86 %, allele G – 20 people (57.14 %); genotypes G/G, A/A and G/G had 15 (42.86 %), 7 (20 %) and 13 (37.14 %) persons respectively. 42 patients with CHD were allele A, which made 36.52 %, allele G – 73 patients (63.48 %). Genotypes G/G, A/A and G/G had 47 (40.87 %), 20 (17.39 %) and 48 (41.74%) patients with CHD respectively. In group of patients with combination of CHD and obesity 71 patients (31.98 %) were allele A, allele G – 151 people (68.02 %); genotypes G/G, A/A and G/G – 81 (36.49 %), 33 (14.87 %) and 108 (48.64 %) respectively. Comparison of leptin gene (Arg223Gln) alleles and genotypes polymorphism frequency of detection between groups showed the reliable differences of alleles A, G and a genotype G/G. In patients with CHD and obesity allele G was 10.88 % more and genotype G/G was 11.5 % more, than in the control group. Allele A was 10.88 % more in the control group, than in patients with CHD and obesity (p < 0.05). Reliable differences between group of CHD patients and the control group in distribution of detected alleles and genotypes frequency of leptin gene (Arg223Gln) polymorphism were not found (p < 0.05). Conclusions. By results of the study allele G and a genotype G/G of leptin gene (Arg223Gln) polymorphism in patients with CHD has been associated with obesity.

Highlights

  • Comparison of leptin gene (Arg223Gln) alleles and genotypes polymorphism frequency of detection between groups showed the reliable differences of alleles A, G and a genotype G/G

  • By results of the study allele G and a genotype G/G of leptin gene (Arg223Gln) polymorphism in patients with coronary heart disease (CHD) has been associated with obesity

  • Поліморфізм A223G локалізований у 6 екзоні екстрацелюлярної ділянки рецептора лептину в С домені, що має лептин-зв’язувальну зону та призводить до одиничної амінокислотної заміни глютаміну (Gln) на аргінін (Arg) у кодоні 223 й зумовлює вимірювання функціональної активності лептинового рецептора [3,4]

Read more

Summary

Introduction

Групу порівняння становили 115 хворих на ІХС із нормальною масою тіла. До контрольної групи увійшло 35 практично здорових осіб. У дослідження не включали хворих із важкою супутньою патологією органів дихання, травлення, нирок та осіб з онкологічними захворюваннями. Вірогідних відмінностей між групою хворих на ІХС і контрольною групою щодо розподілу частоти виявлення алелів і генотипів поліморфізму гена лептину (Arg223Gln) не знайдено (p > 0,05). Алель G і генотип G/G поліморфізму гена лептину (Arg223Gln) у хворих на ІХС асоційовано з наявністю ожиріння. Группу сравнения составили 115 больных ИБС с нормальной массой тела. В исследование не включали больных с тяжёлой сопутствующей патологией органов дыхания, пищеварения, почек и лиц с онкологическими заболеваниями. Достоверных различий между группой больных ИБС и контрольной группой по распределению частоты выявления аллелей и генотипов полиморфизма гена лептина (Arg223Gln) найдено не было (p > 0,05)

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.